Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OLX301D
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.
Brand Name : OLX301D
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : OLX301D
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?